Molecular Targeting Chemotherany for Glioblastoma

Total Page:16

File Type:pdf, Size:1020Kb

Molecular Targeting Chemotherany for Glioblastoma Molecular targeting chemotherany for glioblastoma ORIGINAL ARTICLE Annals of Cancer Research and Therapy Tatsunori Okamura*1), Masahiko Nishiyama・Katsuyuki Suzuki・ Wataru Yamamoto*2), Kaoru Kurisu*1) We investigated the critical determinants of cytotoxic activity for cisplatin (CDDP),mitomycin C (MMC),and nimustinehydrochloride (ACNU), which are commonlyused to treat malignant glioma.In 10human cancer cell lines, glutathione S-transferase (GST)was a significantresistance factor for CDDP. MMC activity was found to be determined through the balance between activation by NADPH:quinone oxidoreductase (DTD)and inactivationby GST, while NADPH:cytochrome P450 reductase (P-450)was importantin ACNUresistance. Two glioblastoma cell lines, T98G and U-251 MG, showed remarkably high levels of these 3 enzymes and glutathione (GSH),thus being moderately sensitive to MMCand resistant to CDDPand ACNU.Inhibition of these target enzymes caused an increase of the efficacy of each drug. KW2149,a novel MMCanalogue activated by GSH, was active against T98G and U-251MGcells due to their high GSH levels. Moleculartargeting to seek the best treatment modalityor the most active drug may contribute to improvingthe effective- ness of glioma chemotherapy. Ann Cancer Res Ther 6 (1): 27~31, 1997/Received 7 July 1997, Accepted 28 July 1997 Kay words: glioblastoma, drug resisance, ACNU, cisplatin, mitomycin C Chemotherapy has played no real role in the treatment metyrapone were obtained from Sigma, (St. Louis, MO). of malignant glioma1). Although considerable efforts have been directed towards understanding the mechanism(s) of Cell lines cellular resistance, the details remain unclear. In the Two human glioblastoma cell lines, T98G and U-251 present study, we attempted to clarify the biochemical MG, were kindly provided by Dr. S. Hama (National characteristics of gliomas in relation to drug resistance in Cancer Center Research Institute, Tokyo). A human oral order to select the most active drug and determine the epidermoid carcinoma line, KB, was kindly provided by critical factor(s) related to the cytotoxicity of cisplatin Dr. S. Akiyama (Kagoshima University). A human (CDDP), mitomycin C (MMC), and nimustine hydroch- myelogenous leukemia cell line, K562, and multidrug loride (ACNU) so as to develop ways of enhancing their resistant variant, K562/DOX, were kindly provided by actions. The investigation of molecular target(s) was Dr. T. Tsuruo (Tokyo University). Human colon focused on redox cycle-related enzymes. adenocarcinoma lines, COLO201 and COLO320DM, and the human gastric adenocarcinoma line, MKN45, were Materials and methods obtained from the Japanese Cancer Research Resources Bank. The HSC-42, HEC-46, HCC-48, and HCC-50 cell Drugs lines established by Dr. K. Yanagihara (Hiroshima All chemicals used were of analytical grade. Mitomycin University) were kindly provided by their originator. C (MMC) and 7-N-{{2-{[2-(γ-L-glutamylamino) ethyl] dithio}ethyl}} mitomycin C (KW2149) were provided Cytotoxicity assay by Kyowa Hakko Kogyo, (Tokyo, Japan). Nimustine Exponentially growing cells were concentrated to 5× hydrochloride (ACNU) was provided by Sankyo Co., 106/ml and exposed to the indicated drug concentrations (Tokyo, Japan). Cisplatin (CDDP) was provided by for 30min. After two washes in drug-free medium, cells Bristol-Myers-Squibb, (New York, NY). Ethacrynic acid were resuspended at a concentration of 2.5×104/ml in was obtained from Banyu, (Tokyo, Japan). Dichrolo- RPMI-1640 with 10% fetal bovine serum (FBS), and were phenolindophenol (DCPIP), dicumarol (DIC), and seeded into 24-well plates. After 72hr of incubation in fresh medium at 37℃, surviving cells were counted by a Coulter counter and by trypan blue exclusion. *1)Department of Neurosurgery , Hiroshima University School of Medi- cine Assays of enzymatic activity *2)Department of Biochemistry and Biophysics , Research Institute for Radiation Biology and Medicine, Hiroshima University NADPH: quinone oxidoreductase (DTD), NADPH: Correspondence to: Tatsunori Okamura, Department of Neurosurg- cytochrome P-450 reductase (P-450) and glutathione ery, Hiroshima University School of Medicine, 1-2-3 Kasumi, Minami- ku, Hiroshima 734, Japan. S-transferase (GST) activities were measured by the proce- Molecular targeting of glioblastoma chemotherapy 27 dure of Belcourt et al.2) with some modifications. The protein content was measured using the Bio-Rad protein assay (Bio-Rad Laboratory, Hercules, CA). Cytosolic fractions were prepared at 0-4℃ for measure- ment of DTD activity. The reaction mixture included 0.025M Tris-HCl (pH 7.4), 0.7mg/ml crystalline bovine serum albumin, 0.2mM NADPH, 0.01% Tween 20, 5μM flavin adenine dinucleotide, and 40μM DCPIP. Reac- tions were performed at 25℃ in a 3-ml volume in the presence or absence of 20μM DIC and DTD activity was measured as the DIC-sensitive reduction of DCPIP. The velocity of DCPIP reduction was measured by spectro- photometry at 600nm. P-450 was measured using cyto- chrome c as the electron acceptor. Exponentially growing cells (5×106) were washed twice and resuspended in 2ml Fig. 1 Resistance to CDDP in relation to NADPH: of phosphate-buffered saline (138mM NaCl/2.7mM cytochrome P450 reductase (P-450), NADPH: quinone KCl/10mM Na2HPO4/1.8mM KH2PO4, pH 7.4). Cells oxidoreductase (DTD), glutathione S-transferase (GST), were sonicated in three 10sec bursts with 1min of cooling and glutathione (GSH). Only the GST level was significant for CDDP resistance in on ice between each sonication. The reaction mixture (1 10human cancer cell lines. ml) contained 100mM phosphoric acid-potassium buffer (pH 75), 20μM cytochrome c, 100μM NADPH as an electron donor, and 1μM rotenone. The reaction was 5'-dithiobis-(2-nitrobenzolic acid) (Sigma), and glutath- initiated by addition of NADPH at 25℃, and the reduc- ione reductase (Sigma, 0.5units/ml). The optical density tion of cytochrome c was followed spectrophotometrically at 412nm (A412) was monitored for 3min at 20-sec at 550nm for 5min. For measurement of total GST intervals, and the GSH content was calculated from the activity, exponentially growing cells (1×107) were wa- rate of change in absorbance using a standard curve for shed with phosphate-buffered saline and resuspended in each experiment. 500μl of 10mM Tris-HCl (pH 7.8) containing 0.2M NaCl. The resuspended cells were sonicated for 30sec, Results and the solution was centrifuged at 105,000×g for 45 min to collect the supernatant. The enzyme reaction was To clarify the critical determinants of drug action, the carried out in a 1-ml cuvette. To give a final concentration activities of P-450, DTD and GST, and the total GSH of 1mM, 80mM 1-chloro-2, 4-dinitrobenzene (CDNB) content were assessed in relation to the cytotoxicity of was diluted in 0.1M potassium phosphate buffer (pH 6.5), CDDP, MMC, and ACNU. In the 10cultured human after which the sample was added. Glutathione (GSH, 2.5 cancer cell lines studied, the cellular GST activity seemed mM) was added to the warmed solution at 25℃. The to be a critical determinant of CDDP resistance (Fig. 1). optical density at 340nm (A340) was monitored and GST Only GST activity was correlated with the IC50 value of activity was calculated from the enzyme- dependent CDDP. To clarify the extent to which GST accounted for change in absorption. CDDP resistance, the effect of inhibition of this enzyme was studied. Inhibition of GST by 3.3μM ethacrynic acid Cellular GSH content (EA) caused a significant increase of CDDP-induced The total cellular GSH content was measured by an cytotoxicity, while treatment with 3.3μM EA alone inhib- enzyme recycling assay3). Exponentially growing cells ited cell growth by less than 10%. These results suggested (1-5×106) were suspended in 300μl of phosphate- that GST may be a significant factor in CDDP resistance . EDTA solution (125mM KH2PO4, 6.3mM EDTA, pH MMC activity was found to be determined through the 7.5). The resuspended cells were sonicated, and 100μl of balance between activation by DTD and inactivation by 12% 5-sulfosalicylic acid (Wako, Osaka) was added to GST. DTD activity was well related to MMC sensitivity, each sample tube. The solution was mixed and allowed to while GST activity was correlated with the degree of precipitate for 2 to 3hr on ice. After centrifugation at resistance to MMC (Fig. 2) . Inhibition of DTD activity by 10,000×g for 15min, protein-free lysates were obtained. a non-toxic concentration of DIC (50μM) significantly The enzymatic assay of GSH was carried out at 25℃ in a decreased MMC-induced cytotoxicity in 8 of the 10cell 1-ml cuvette containing 125mM KH2PO4, 6.3mM EDTA, lines (not COLO201 and COLO320DM) . In contrast, 0.21mM NADPH (Wako, Osaka, Japan), 0.6mM 5, inhibition of GST activity by 3 .3μM EA caused a signifi- 28 Annals of Cancer Research and Therapy Vol. 6 No. 1 1997 Fig. 4 Cellular activities of NADPH: cytochrome P450 Fig. 2 Resistance to mitomycin C (MMC) in relation to reductase (P-450), NADPH: quinone oxidoreductase NADPH: cytochrome P450 reductase (P-450), NADPH: (DTD), glutathione S-transferase (GST), and glutathione quinone oxidoreductase (DTD), glutathione S-transferase (GSH) content. (GST), and glutathione (GSH). Glioblastoma T98G and U-251MG cells had relatively Cellular DTD activity was correlated with MMC-induced high levels of DTD, P-450, GST, and GSH. cytotoxicity, while GST activity was related to resistance to MMC in 10human cancer cell lines. Fig. 5 Cellular sensitivity to mitomycin C (MMC), cis- Fig. 3 Resistance to nimustine hydrochloride (ACNU) platinum (CDDP), and nimustine hydrochloride in relation to NADPH: cytochrome P450 reductase (P- (ACNU). 450), NADPH: quinone oxidoreductase (DTD), glutath- Glioblastoma T98G and U-25IMG cells were moderately ione S-transferase (GST), and glutathione (GSH). sensitive to MMC, but were resistant to CDDP and P-450 activity was important for ACNU resistance in 10 ACNU. human cancer cell lines. cell lines investigated. These results indicated that the cant increase of MMC activity in 9 cell lines (not K562/ resistance factors were GST for CDDP, DTD and GST DOX).
Recommended publications
  • Relevance Network Between Chemosensitivity and Transcriptome in Human Hepatoma Cells1
    Vol. 2, 199–205, February 2003 Molecular Cancer Therapeutics 199 Relevance Network between Chemosensitivity and Transcriptome in Human Hepatoma Cells1 Masaru Moriyama,2 Yujin Hoshida, topoisomerase II ␤ expression, whereas it negatively Motoyuki Otsuka, ShinIchiro Nishimura, Naoya Kato, correlated with expression of carboxypeptidases A3 Tadashi Goto, Hiroyoshi Taniguchi, and Z. Response to nimustine was associated with Yasushi Shiratori, Naohiko Seki, and Masao Omata expression of superoxide dismutase 2. Department of Gastroenterology, Graduate School of Medicine, Relevance networks identified several negative University of Tokyo, Tokyo 113-8655 [M. M., Y. H., M. O., N. K., T. G., H. T., Y. S., M. O.]; Cellular Informatics Team, Computational Biology correlations between gene expression and resistance, Research Center, Tokyo 135-0064 [S. N.]; and Department of which were missed by hierarchical clustering. Our Functional Genomics, Graduate School of Medicine, Chiba University, results suggested the necessity of systematically Chiba 260-8670 [N. S.], Japan evaluating the transporting systems that may play a major role in resistance in hepatoma. This may provide Abstract useful information to modify anticancer drug action in Generally, hepatoma is not a chemosensitive tumor, hepatoma. and the mechanism of resistance to anticancer drugs is not fully elucidated. We aimed to comprehensively Introduction evaluate the relationship between chemosensitivity and Hepatoma is a major cause of death even in developed gene expression profile in human hepatoma cells, by countries, and its incidence is increasing (1). Despite the using microarray analysis, and analyze the data by progress of therapeutic technique (2), the efficacy of radical constructing relevance networks. therapy is hampered by frequent recurrence and advance of In eight hepatoma cell lines (HLE, HLF, Huh7, Hep3B, the tumor (3).
    [Show full text]
  • Title Second-Line Chemotherapy for Small-Cell Lung Cancer
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Kyoto University Research Information Repository Second-line chemotherapy for small-Cell Lung Cancer Title (SCLC). Author(s) Kim, Young Hak; Mishima, Michiaki Citation Cancer treatment reviews (2011), 37(2): 143-150 Issue Date 2011-04 URL http://hdl.handle.net/2433/137220 Right © 2010 Elsevier Ltd Type Journal Article Textversion author Kyoto University Second-line Chemotherapy for Small-Cell Lung Cancer (SCLC) Young Hak Kim and Michiaki Mishima Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan For reprints and all correspondence: Young Hak Kim Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan Phone: +81-75-751-3830; Fax: +81-75-751-4643; E-mail: [email protected] Running title: Second-line Chemotherapy for SCLC Key words: small-cell lung cancer, relapsed, chemotherapy, second line, sensitive, refractory 1 Abstract Although small-cell lung cancer (SCLC) generally shows an excellent response to initial chemotherapy, most patients finally relapse and salvage chemotherapy is considered. Usually, the response to salvage chemotherapy significantly differs between sensitive and refractory relapse. Sensitive relapse is relatively chemosensitive and re-challenge with the same drugs as used in the initial chemotherapy has been used historically, while refractory relapse is extremely chemoresistant and its prognosis has been abysmal. To date, a number of clinical trials have been carried out for relapsed SCLC; however, the number of randomized trials is quite limited.
    [Show full text]
  • Nimustine Induces DNA Breaks and Crosslinks in NIH/3T3 Cells
    International Journal of Bioscience, Biochemistry and Bioinformatics, Vol. 3, No. 3, May 2013 Nimustine Induces DNA Breaks and Crosslinks in NIH/3T3 Cells Lin-Na Zhao, Xue-Chai Chen, Yan-Yan Zhong, Qin-Xia Hou, and Ru-Gang Zhong study of drug-induced DNA cross-linking to reveal the Abstract—The relationship between carcinogenicity and difference between the nitrosourea anticancer mechanism DNA interstrand cross-links of nitrosoureas is poorly defined. and carcinogenic role. 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3- (2-chloroethyl)- ACNU was discovered in 1974 as the first water-soluble 3- nitrosourea (ACNU, nimustine) is one of nitrosoureas used in nitrosourea compound [11], and mainly used in the clinic of the treatment of high-grade gliomas. It has the capability of causing DNA interstrand cross-links (ICLs) to kill cancer cells. glioblastoma patients before the introduction of But it can also cause the generation of secondary tumors with 8-carbamoyl-3-methylimidazo [5, 1-d]-1, 2, 3, carcinogenic side effects. In present study, we investigated DNA 5-tetrazin-4(3H) -one (temozolomide, TMZ) because of its interstrand cross-links, DNA double-strand breaks and cell high permeability across blood-brain barrier (BBB) and good cycle phase in NIH/3T3 cells from the primary mouse cytotoxic activity for gliomas [12]-[13]. BCNU always embryonic fibroblast cells induced by ACNU. This result induces two major types of genotoxic damage to the cell: indicated that the concentration of 60 and 75μg/ml of ACNU could be detected significantly ICLs, and the γ-H2AX has the DNA mono adducts and DNA interstrand cross-links.
    [Show full text]
  • Nanoconjugates Able to Cross the Blood-Brain Barrier Alexander H Stegh, Janina Paula Luciano, Samuel A
    (12) STANDARD PATENT (11) Application No. AU 2017216461 B2 (19) AUSTRALIAN PATENT OFFICE (54) Title Nanoconjugates Able To Cross The Blood-Brain Barrier (51) International Patent Classification(s) A61K 31/7088 (2006.01) A61K 48/00 (2006.0 1) A61K 9/00 (2006.01) A61P 35/00 (2006.01) (21) Application No: 2017216461 (22) Date of Filing: 2017.08.15 (43) Publication Date: 2017.08.31 (43) Publication Journal Date: 2017.08.31 (44) Accepted Journal Date: 2019.10.17 (62) Divisional of: 2012308302 (71) Applicant(s) NorthwesternUniversity (72) Inventor(s) Mirkin, Chad A.;Ko, Caroline H.;Stegh, Alexander;Giljohann, David A.;Luciano, Janina;Jensen, Sam (74) Agent / Attorney WRAYS PTY LTD, L7 863 Hay St, Perth, WA, 6000, AU (56) Related Art US 2010/0233084 Al LJUBIMOVA et al. "Nanoconjugate based on polymalic acid for tumor targeting", Chemico-Biological Interactions, 2008, Vol. 171, Pages 195-203. WO 2011/028847 Al BONOU et al. "Nanotechnology approach for drug addiction therapy: Gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons", PNAS, 2009, Vol. 106, No. 14, Pages 5546-5550. PATIL et al. "Temozolomide Delivery to Tumor Cells by a Multifunctional Nano Vehicle Based on Poly(#-L-malic acid)", Pharmaceutical Research, 2010, Vol. 27, Pages 2317-2329. ABSTRACT Polyvalent nanoconjugates address the critical challenges in therapeutic use. The single-entity, targeted therapeutic is able to cross the blood-brain barrier (BBB) and is thus effective in the treatment of central nervous system (CNS) disorders. Further, despite the tremendously high 5 cellular uptake of nanoconjugates, they exhibit no toxicity in the cell types tested thus far.
    [Show full text]
  • II. Recurring Tumors
    Review Article Open Access J Surg Volume 7 Issue 1 - November 2017 Copyright © All rights are reserved by Alain L Fymat DOI: 10.19080/OAJS.2017.07.555703 Surgical and Non-Surgical Management and Treatment of Glioblastoma: II. Recurring Tumors Alain L Fymat* International Institute of Medicine & Science, USA Submission: October 28, 2017; Published: November 16, 2017 *Corresponding author: Alain L Fymat, International Institute of Medicine and Science, California, USA, Tel: ; Email: Abstract Glioblastoma (also known as glioblastoma multiform) is the most common primary brain tumor in adults. It remains an unmet need in oncology. Complementing an earlier discussion of primary and secondary tumors in both cases of monotherapies and combined therapies, Clinical trials and other reported practices will also be discussed and summarized. Regarding chemotherapy, whereas it has historically surgery,provided conformal little durable radiotherapy, benefit with boron tumors neutron recurring therapy, within intensity several modulated months, forproton brain beam tumors, therapy, the access antiangiogenic is hindered therapy, or even alternating forbidden electric by the presence of the brain protective barriers, chiefly the blood brain barrier. More effective therapies involving other options are required including immunotherapy, adjuvant therapy, gene therapy, stem cell therapy, and intra-nasal drug delivery. field therapy, ...without neglecting palliative therapies. Research conducted in these and other options is also reviewed to include microRNA,
    [Show full text]
  • Review Article
    REVIEW ARTICLE Chemotherapy advances in small-cell lung cancer Bryan A. Chan1,2, Jermaine I. G. Coward1,2,3 1Mater Adult Hospital, Department of Medical Oncology, Raymond Terrace, Brisbane, QLD 4101, Australia; 2School of Medicine, University of Queensland, St Lucia, Brisbane, QLD 4072, Australia; 3Inflammation & Cancer Therapeutics Group, Mater Research, Level 4, Translational Research Institute, Woolloongabba, Brisbane, QLD 4102, Australia ABSTRACT Although chemotherapeutic advances have recently been heralded in lung adenocarcinomas, such success with small-cell lung cancer (SCLC) has been ominously absent. Indeed, the dismal outlook of this disease is exemplified by the failure of any significant advances in first line therapy since the introduction of the current standard platinum-etoposide doublet over 30 years ago. Moreover, such sluggish progress is compounded by the dearth of FDA-approved agents for patients with relapsed disease. However, over the past decade, novel formulations of drug classes commonly used in SCLC (e.g. topoisomerase inhibitors, anthracyclines, alkylating and platinum agents) are emerging as potential alternatives that could effectively add to the armamentarium of agents currently at our disposal. This review is introduced with an overview on the historical development of chemotherapeutic regimens used in this disease and followed by the recent encouraging advances witnessed in clinical trials with drugs such as amrubicin and belotecan which are forging new horizons for future treatment algorithms. KEY WORDS Small cell lung cancer (SCLC); amrubicin; belotecan; picoplatin; relapsed SCLC J Thorac Dis 2013;5(S5):S565-S578. doi: 10.3978/j.issn.2072-1439.2013.07.43 Introduction cigarette smoking 20 years prior, but is now slowly decreasing due to changing smoking patterns (2).
    [Show full text]
  • E-Table 1. Drug Classification Category Name Generic Name
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax e-Table 1. Drug classification Category Name Generic Name Antiplatelets clopidogrel, cilostazol, ticlopidine2, beraprost, beraprost–long acting, complavin Anticoagulants 2,3 dabigatran Statins1,2,3 atorvastatin2, simvastatin, pitavastatin, fluvastatin, pravastatin, rosuvastatin, amlodipine/atorvastatin Sodium channel blockers4,5† mexiletine, aprindine, cibenzoline Beta blocker acebutolol2 Class III antiarrhythmic drugs amiodarone1–6 Calcium channel blockers bepridil1, amlodipine/atorvastatin, telmisartan/amlodipine, valsartan/amlodipine, valsartan/cilnidipine, candesartan/amlodipine Angiotensin/converting enzyme enalapril inhibitor2‡ Thiazides trichlormethiazide, hydrochlorothiazide3,5, benzylhydrochlorothiazide/reserpine/carbazochrome, mefruside, telmisartan/hydrochlorothiazide, valsartan/hydrochlorothiazide, candesartan/hydrochlorothiazide, candesartan/trichlormethiazide, losartan/hydrochlorothiazide NSAIDs diclofenac2, celecoxib, loxoprofen, etodolac, nabumetone, pranoprofen Anti-rheumatics actarit, iguratimod, tofacitinib, penicillamine2–5, leflunomide1,3, sodium aurothiomalate2–6#, bucillamine Leukotriene receptor antagonist2* pranlukast 5-ASA mesalazine, salazosulfapyridine5 Tricyclic antidepressant Imipramine5, cromipramine, maprotiline Antiepileptics valproate, phenytoin2,3,5, ethotoin, carbamazepine2–5, zonisamide Interferon1,2,3
    [Show full text]
  • Ep 3067054 A1
    (19) TZZ¥ZZ_T (11) EP 3 067 054 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 14.09.2016 Bulletin 2016/37 A61K 31/505 (2006.01) A61K 31/55 (2006.01) A61K 38/17 (2006.01) A61P 35/00 (2006.01) (21) Application number: 16156278.0 (22) Date of filing: 10.09.2008 (84) Designated Contracting States: • MIKULE, Keith AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Cambridge, MA Massachusetts 02139 (US) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT • LI, Youzhi RO SE SI SK TR Westwood, MA 02090 (US) (30) Priority: 10.09.2007 US 971144 P (74) Representative: Finnie, Isobel Lara 13.12.2007 US 13372 Haseltine Lake LLP Lincoln House, 5th Floor (62) Document number(s) of the earlier application(s) in 300 High Holborn accordance with Art. 76 EPC: London WC1V 7JH (GB) 08830633.7 / 2 200 431 Remarks: (71) Applicant: Boston Biomedical, Inc. This application was filed on 18-02-2016 as a Cambridge, MA 02139 (US) divisional application to the application mentioned under INID code 62. (72) Inventors: • LI, Chiang, Jia Cambridge, MA Massachusetts 02141 (US) (54) NOVEL COMPOSITIONS AND METHODS FOR CANCER TREATMENT (57) The present invention relates to the composition and methods of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer. EP 3 067 054 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 067 054 A1 Description REFERENCE TO RELATED APPLICATIONS 5 [0001] This application claims priority to and the benefit of U.S.
    [Show full text]
  • Current Challenges and Opportunities in Treating Glioblastomas
    Supplemental Material can be found at: /content/suppl/2018/04/23/70.3.412.DC1.html 1521-0081/70/3/412–445$35.00 https://doi.org/10.1124/pr.117.014944 PHARMACOLOGICAL REVIEWS Pharmacol Rev 70:412–445, July 2018 Copyright © 2018 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: ERIC L. BARKER Current Challenges and Opportunities in Treating Glioblastomas Andrea Shergalis, Armand Bankhead, III, Urarika Luesakul, Nongnuj Muangsin, and Nouri Neamati Department of Medicinal Chemistry, College of Pharmacy, North Campus Research Complex, Ann Arbor, Michigan (A.S., U.L., N.N.); Biostatistics Department and School of Public Health, University of Michigan, Ann Arbor, Michigan (A.B.); and Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand (U.L., N.M.) Abstract ...................................................................................413 I. Introduction . ..............................................................................413 II. Current Treatment Options for Glioblastoma ...............................................414 III. Molecular Diagnostic Signature of Glioblastoma . ..........................................419 IV. Characteristics of Protein Expression in Glioblastoma . .....................................419 V. Emerging Targets in Glioblastoma . ......................................................422 A. Biomarker Identification . ............................................................422 B.
    [Show full text]
  • EANO Guidelines on the Diagnosis and Treatment of Diffuse Gliomas of Adulthood
    EVIDENCE-BASED GUIDELINES OPEN EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood Michael Weller1 ✉ , Martin van den Bent 2, Matthias Preusser 3, Emilie Le Rhun4,5,6,7, Jörg C. Tonn8, Giuseppe Minniti 9, Martin Bendszus10, Carmen Balana 11, Olivier Chinot12, Linda Dirven13,14, Pim French 15, Monika E. Hegi 16, Asgeir S. Jakola 17,18, Michael Platten19,20, Patrick Roth1, Roberta Rudà21, Susan Short 22, Marion Smits 23, Martin J. B. Taphoorn13,14, Andreas von Deimling24,25, Manfred Westphal26, Riccardo Soffietti 21, Guido Reifenberger27,28 and Wolfgang Wick 29,30 Abstract | In response to major changes in diagnostic algorithms and the publication of mature results from various large clinical trials, the European Association of Neuro-Oncology (EANO) recognized the need to provide updated guidelines for the diagnosis and management of adult patients with diffuse gliomas. Through these evidence-based guidelines, a task force of EANO provides recommendations for the diagnosis, treatment and follow- up of adult patients with diffuse gliomas. The diagnostic component is based on the 2016 update of the WHO Classification of Tumors of the Central Nervous System and the subsequent recommendations of the Consortium to Inform Molecular and Practical Approaches to CNS Tumour Taxonomy — Not Officially WHO (cIMPACT- NOW). With regard to therapy, we formulated recommendations based on the results from the latest practice-changing clinical trials and also provide guidance for neuropathological and neuroradiological assessment. In these guidelines, we define the role of the major treatment modalities of surgery, radiotherapy and systemic pharmacotherapy, covering current advances and cognizant that unnecessary interventions and expenses should be avoided.
    [Show full text]
  • Development of Newly Synthesized Chromone Derivatives with High Tumor Specificity Against Human Oral Squamous Cell Carcinoma
    medicines Review Development of Newly Synthesized Chromone Derivatives with High Tumor Specificity against Human Oral Squamous Cell Carcinoma Yoshiaki Sugita 1,*, Koichi Takao 1, Yoshihiro Uesawa 2,* , Junko Nagai 2 , Yosuke Iijima 3, Motohiko Sano 4 and Hiroshi Sakagami 5,* 1 Department of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan; [email protected] 2 Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo 204-858, Japan; [email protected] 3 Department of Oral and Maxillofacial Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe 350-8550, Japan; [email protected] 4 Division of Applied Pharmaceutical Education and Research, Hoshi University, Tokyo 142-8501, Japan; [email protected] 5 Meikai University Research Institute of Odontology (M-RIO), 1-1 Keyakidai, Sakado, Saitama 350-0283, Japan * Correspondence: [email protected] (Y.S.); [email protected] (Y.U.); [email protected] (H.S.); Tel.: +81-492-717-254 (Y.S.); +81-424-958-983 (Y.U.); +81-492-792-758 (H.S.) Received: 3 August 2020; Accepted: 24 August 2020; Published: 26 August 2020 Abstract: Since many anticancer drugs show severe adverse effects such as mucositis, peripheral neurotoxicity, and extravasation, it was crucial to explore new compounds with much reduced adverse effects. Comprehensive investigation with human malignant and nonmalignant cells demonstrated that derivatives of chromone, back-bone structure of flavonoid, showed much higher tumor specificity as compared with three major polyphenols in the natural kingdom, such as lignin-carbohydrate complex, tannin, and flavonoid. A total 291 newly synthesized compounds of 17 groups (consisting of 12 chromones, 2 esters, and 3 amides) gave a wide range of the intensity of tumor specificity, possibly reflecting the fitness for the optimal 3D structure and electric state.
    [Show full text]
  • Promising Survival for Patients with Glioblastoma Multiforme Treated with Individualised Chemotherapy Based on in Vitro Drug Sensitivity Testing
    British Journal of Cancer (2003) 89, 1896 – 1900 & 2003 Cancer Research UK All rights reserved 0007 – 0920/03 $25.00 www.bjcancer.com Promising survival for patients with glioblastoma multiforme treated with individualised chemotherapy based on in vitro drug sensitivity testing Clinical *,1 2 3 1 Y Iwadate , S Fujimoto , H Namba and A Yamaura 1Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba 260-8670, Japan; 2Division of 3 Chemotherapy, Chiba Cancer Center, Nitona 666-2, Chuo-ku, Chiba 260-8717, Japan; Department of Neurosurgery, Hamamatsu University School of Medicine, Handayama 1-20-1, Hamamatsu 431-3192, Japan We retrospectively investigated the efficacy and feasibility of individualised chemotherapy based on in vitro drug sensitivity testing (DST) for patients with glioblastoma multiforme. A total of 40 consecutive patients with glioblastoma multiforme (GM) were enrolled into this study between January 1995 and December 2000. The flow cytometric (FCM) detection of apoptosis was used to determine the in vitro sensitivity of tumour cells obtained at surgery to 30 different kinds of anticancer agents. From the results of FCM assay, an in vitro best regimen was prospectively selected. All the patients concurrently received the individualised chemotherapy with the in vitro best regimen and 60 Gy of conventional radiation therapy. Of the 31 assessable patients, eight patients (26%) achieved partial response, and 20 patients (65%) had stable disease. The median survival time was 20.5 months. The individualised chemotherapy based on in vitro DST was associated with favourable survival time for the patients with GM compared with the reported results of conventional therapy regimens.
    [Show full text]